Rigel Provides Business Update and 2026 Outlook [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
In the dose escalation phase of the Phase 1b study of R289 in patients with lower-risk MDS, R289 continues to be generally well tolerated. RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses =500 mg QD, including 40% (2/5) in the 500 mg BID dose group Enrollment in the dose expansion phase of the Phase 1b study is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026 2026 Outlook: Rigel anticipates full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year SOUTH SAN FRANCISCO, Calif. Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the four
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? [Yahoo! Finance]Yahoo! Finance
- Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Rigel Provides Business Update and 2026 OutlookPR Newswire
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Rigel to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
RIGL
Earnings
- 11/4/25 - Beat
RIGL
Sec Filings
- 1/12/26 - Form 8-K
- 12/29/25 - Form 4
- 12/10/25 - Form 8-K
- RIGL's page on the SEC website